| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 80 | 2023 | 410 | 18.460 |
Why?
|
| Antirheumatic Agents | 46 | 2023 | 167 | 8.420 |
Why?
|
| Osteoarthritis, Knee | 26 | 2019 | 162 | 8.150 |
Why?
|
| Rheumatic Diseases | 19 | 2023 | 54 | 5.230 |
Why?
|
| Arthroplasty, Replacement, Knee | 18 | 2016 | 76 | 4.940 |
Why?
|
| Osteoporosis | 14 | 2022 | 241 | 4.000 |
Why?
|
| Rheumatology | 24 | 2024 | 72 | 3.940 |
Why?
|
| Neoplasms | 60 | 2023 | 15193 | 2.950 |
Why?
|
| Lupus Erythematosus, Systemic | 6 | 2023 | 223 | 2.930 |
Why?
|
| Antineoplastic Agents, Immunological | 12 | 2020 | 1249 | 2.800 |
Why?
|
| Patient Education as Topic | 12 | 2021 | 748 | 2.710 |
Why?
|
| Arthritis | 7 | 2022 | 139 | 1.910 |
Why?
|
| Immunotherapy | 14 | 2022 | 3341 | 1.810 |
Why?
|
| Musculoskeletal Diseases | 7 | 2023 | 81 | 1.750 |
Why?
|
| Patient Satisfaction | 18 | 2021 | 915 | 1.690 |
Why?
|
| Humans | 284 | 2024 | 261506 | 1.640 |
Why?
|
| Methotrexate | 12 | 2018 | 999 | 1.610 |
Why?
|
| Hepatitis B | 5 | 2019 | 258 | 1.530 |
Why?
|
| Myositis | 3 | 2021 | 79 | 1.510 |
Why?
|
| Aged | 107 | 2022 | 70117 | 1.410 |
Why?
|
| Immunologic Factors | 10 | 2020 | 649 | 1.400 |
Why?
|
| Scleroderma, Systemic | 8 | 2022 | 134 | 1.380 |
Why?
|
| Pain | 15 | 2017 | 1658 | 1.350 |
Why?
|
| Bone Density | 7 | 2022 | 476 | 1.300 |
Why?
|
| Multimedia | 2 | 2019 | 25 | 1.300 |
Why?
|
| Self Efficacy | 5 | 2021 | 298 | 1.290 |
Why?
|
| Patient Compliance | 8 | 2014 | 667 | 1.290 |
Why?
|
| Video Recording | 3 | 2021 | 267 | 1.290 |
Why?
|
| Quality of Life | 21 | 2021 | 4532 | 1.290 |
Why?
|
| Middle Aged | 116 | 2023 | 86204 | 1.280 |
Why?
|
| Professional-Patient Relations | 3 | 2016 | 124 | 1.270 |
Why?
|
| Diphosphonates | 4 | 2020 | 262 | 1.260 |
Why?
|
| Male | 138 | 2023 | 123000 | 1.240 |
Why?
|
| Biological Products | 10 | 2020 | 274 | 1.230 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2021 | 598 | 1.220 |
Why?
|
| Pain Measurement | 13 | 2018 | 953 | 1.220 |
Why?
|
| Osteoporotic Fractures | 2 | 2022 | 37 | 1.220 |
Why?
|
| Running | 2 | 2018 | 46 | 1.210 |
Why?
|
| Female | 144 | 2023 | 141928 | 1.200 |
Why?
|
| Smoking Cessation | 2 | 2023 | 712 | 1.180 |
Why?
|
| Autoimmune Diseases | 3 | 2023 | 402 | 1.180 |
Why?
|
| Severity of Illness Index | 22 | 2021 | 4320 | 1.160 |
Why?
|
| Cell Cycle Checkpoints | 3 | 2018 | 278 | 1.100 |
Why?
|
| Patient Readmission | 2 | 2021 | 548 | 1.050 |
Why?
|
| Decision Support Techniques | 5 | 2019 | 622 | 1.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 11 | 2021 | 1209 | 1.000 |
Why?
|
| Medicare | 6 | 2022 | 860 | 1.000 |
Why?
|
| Practice Guidelines as Topic | 14 | 2020 | 2403 | 0.990 |
Why?
|
| Consumer Health Information | 3 | 2022 | 52 | 0.980 |
Why?
|
| Decision Making | 9 | 2021 | 1287 | 0.970 |
Why?
|
| Internet | 7 | 2022 | 706 | 0.960 |
Why?
|
| Knee Joint | 7 | 2019 | 161 | 0.950 |
Why?
|
| Acupuncture Therapy | 3 | 2016 | 89 | 0.940 |
Why?
|
| Osteoarthritis | 7 | 2017 | 94 | 0.920 |
Why?
|
| Tobacco Use Cessation | 1 | 2023 | 28 | 0.900 |
Why?
|
| Disability Evaluation | 5 | 2014 | 249 | 0.890 |
Why?
|
| Attitude to Health | 5 | 2012 | 465 | 0.890 |
Why?
|
| Myasthenia Gravis | 2 | 2021 | 99 | 0.880 |
Why?
|
| Social Networking | 1 | 2022 | 28 | 0.850 |
Why?
|
| Pamphlets | 2 | 2021 | 31 | 0.850 |
Why?
|
| Health Status | 6 | 2021 | 590 | 0.840 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2023 | 63 | 0.840 |
Why?
|
| Denosumab | 2 | 2020 | 68 | 0.830 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2021 | 573 | 0.820 |
Why?
|
| Survivors | 5 | 2017 | 1031 | 0.820 |
Why?
|
| Cardiovascular Diseases | 5 | 2020 | 2195 | 0.810 |
Why?
|
| Chondrocalcinosis | 2 | 2019 | 19 | 0.800 |
Why?
|
| CTLA-4 Antigen | 8 | 2020 | 657 | 0.780 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2018 | 600 | 0.780 |
Why?
|
| Acetaminophen | 2 | 2013 | 116 | 0.780 |
Why?
|
| Self Care | 3 | 2021 | 224 | 0.780 |
Why?
|
| Immunosuppressive Agents | 8 | 2023 | 1375 | 0.780 |
Why?
|
| Hepatitis B virus | 4 | 2019 | 217 | 0.780 |
Why?
|
| Cohort Studies | 20 | 2022 | 9244 | 0.780 |
Why?
|
| Prednisone | 3 | 2014 | 984 | 0.770 |
Why?
|
| Monitoring, Physiologic | 3 | 2014 | 502 | 0.770 |
Why?
|
| Communication | 6 | 2012 | 876 | 0.770 |
Why?
|
| Self-Management | 2 | 2021 | 89 | 0.760 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2013 | 126 | 0.760 |
Why?
|
| Comprehension | 3 | 2022 | 120 | 0.750 |
Why?
|
| Adult | 65 | 2023 | 77950 | 0.750 |
Why?
|
| Vaginal Smears | 1 | 2021 | 192 | 0.750 |
Why?
|
| Texas | 19 | 2021 | 6311 | 0.740 |
Why?
|
| Review Literature as Topic | 6 | 2010 | 71 | 0.740 |
Why?
|
| Swimming | 1 | 2019 | 27 | 0.720 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2020 | 37 | 0.720 |
Why?
|
| Self-Help Groups | 1 | 2020 | 37 | 0.720 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2021 | 1538 | 0.720 |
Why?
|
| Fractures, Bone | 2 | 2021 | 291 | 0.720 |
Why?
|
| Hospitalization | 5 | 2021 | 2083 | 0.720 |
Why?
|
| Sarcoidosis | 1 | 2021 | 112 | 0.720 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2023 | 799 | 0.720 |
Why?
|
| Social Support | 4 | 2020 | 560 | 0.710 |
Why?
|
| Arthroplasty, Replacement, Hip | 5 | 2011 | 51 | 0.710 |
Why?
|
| Focus Groups | 9 | 2012 | 256 | 0.690 |
Why?
|
| United States | 24 | 2022 | 15433 | 0.680 |
Why?
|
| Thromboembolism | 1 | 2020 | 155 | 0.680 |
Why?
|
| Surveys and Questionnaires | 22 | 2021 | 5687 | 0.680 |
Why?
|
| Consensus | 9 | 2024 | 978 | 0.670 |
Why?
|
| Peripheral Vascular Diseases | 8 | 2007 | 136 | 0.670 |
Why?
|
| Retrospective Studies | 38 | 2023 | 37905 | 0.670 |
Why?
|
| Myocarditis | 1 | 2021 | 190 | 0.670 |
Why?
|
| Randomized Controlled Trials as Topic | 18 | 2022 | 2594 | 0.660 |
Why?
|
| Osteoarthritis, Hip | 3 | 2014 | 17 | 0.660 |
Why?
|
| Early Detection of Cancer | 3 | 2021 | 1258 | 0.660 |
Why?
|
| Aged, 80 and over | 33 | 2021 | 29902 | 0.660 |
Why?
|
| Health Services Needs and Demand | 4 | 2015 | 244 | 0.650 |
Why?
|
| Absorptiometry, Photon | 3 | 2021 | 239 | 0.650 |
Why?
|
| Physician-Patient Relations | 5 | 2009 | 792 | 0.650 |
Why?
|
| Bone Density Conservation Agents | 4 | 2020 | 198 | 0.650 |
Why?
|
| Quality-Adjusted Life Years | 5 | 2019 | 226 | 0.650 |
Why?
|
| Hip Fractures | 4 | 2001 | 76 | 0.640 |
Why?
|
| Folic Acid | 2 | 2020 | 349 | 0.640 |
Why?
|
| Comorbidity | 14 | 2018 | 2352 | 0.640 |
Why?
|
| Qualitative Research | 5 | 2022 | 556 | 0.640 |
Why?
|
| Medication Adherence | 6 | 2022 | 492 | 0.640 |
Why?
|
| Adaptation, Psychological | 4 | 2020 | 764 | 0.630 |
Why?
|
| Genetic Markers | 1 | 2021 | 974 | 0.630 |
Why?
|
| Psychometrics | 8 | 2016 | 937 | 0.620 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2018 | 3251 | 0.620 |
Why?
|
| Vulnerable Populations | 3 | 2013 | 167 | 0.600 |
Why?
|
| Lipids | 2 | 2012 | 644 | 0.600 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2017 | 48 | 0.580 |
Why?
|
| Ipilimumab | 2 | 2018 | 710 | 0.580 |
Why?
|
| Mass Screening | 9 | 2020 | 1509 | 0.570 |
Why?
|
| Needs Assessment | 1 | 2018 | 233 | 0.570 |
Why?
|
| Treatment Outcome | 41 | 2021 | 32848 | 0.570 |
Why?
|
| Spondylitis, Ankylosing | 7 | 2019 | 29 | 0.570 |
Why?
|
| Patients | 3 | 2018 | 245 | 0.570 |
Why?
|
| Breast Neoplasms | 8 | 2022 | 15694 | 0.570 |
Why?
|
| Clinical Coding | 2 | 2013 | 28 | 0.560 |
Why?
|
| Databases, Factual | 4 | 2021 | 2218 | 0.550 |
Why?
|
| Disease Progression | 10 | 2019 | 6682 | 0.550 |
Why?
|
| Antibodies, Monoclonal | 11 | 2020 | 4367 | 0.550 |
Why?
|
| Evidence-Based Medicine | 7 | 2012 | 1085 | 0.540 |
Why?
|
| Social Media | 1 | 2020 | 203 | 0.540 |
Why?
|
| Complementary Therapies | 1 | 2017 | 126 | 0.530 |
Why?
|
| Folic Acid Antagonists | 2 | 2014 | 45 | 0.530 |
Why?
|
| Prostatic Neoplasms | 5 | 2022 | 5767 | 0.530 |
Why?
|
| Observational Studies as Topic | 4 | 2021 | 140 | 0.530 |
Why?
|
| Social Marketing | 2 | 2013 | 13 | 0.520 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 524 | 0.520 |
Why?
|
| Bone Neoplasms | 3 | 2012 | 2576 | 0.520 |
Why?
|
| Internal-External Control | 3 | 2016 | 110 | 0.520 |
Why?
|
| Research Design | 4 | 2018 | 1544 | 0.510 |
Why?
|
| Arthroplasty, Replacement | 2 | 2007 | 27 | 0.510 |
Why?
|
| Kidney Diseases | 1 | 2020 | 691 | 0.500 |
Why?
|
| Proportional Hazards Models | 8 | 2022 | 4988 | 0.500 |
Why?
|
| Cross-Sectional Studies | 14 | 2023 | 4314 | 0.500 |
Why?
|
| Rituximab | 6 | 2017 | 1528 | 0.500 |
Why?
|
| Emergency Service, Hospital | 2 | 2013 | 1148 | 0.490 |
Why?
|
| Health Promotion | 3 | 2017 | 502 | 0.490 |
Why?
|
| Paraneoplastic Syndromes | 2 | 2011 | 82 | 0.490 |
Why?
|
| Electroacupuncture | 2 | 2012 | 35 | 0.490 |
Why?
|
| Risk Factors | 23 | 2022 | 17523 | 0.480 |
Why?
|
| Virus Activation | 2 | 2014 | 228 | 0.480 |
Why?
|
| Chronic Disease | 6 | 2022 | 1819 | 0.480 |
Why?
|
| Health Personnel | 2 | 2010 | 625 | 0.470 |
Why?
|
| Blood Pressure | 4 | 2017 | 1467 | 0.460 |
Why?
|
| Electronic Health Records | 1 | 2021 | 929 | 0.460 |
Why?
|
| Liver Failure | 2 | 2017 | 140 | 0.460 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2014 | 864 | 0.460 |
Why?
|
| Attitude of Health Personnel | 2 | 2010 | 918 | 0.460 |
Why?
|
| Prospective Studies | 18 | 2021 | 12873 | 0.450 |
Why?
|
| Quality of Health Care | 3 | 2018 | 621 | 0.450 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2021 | 1833 | 0.450 |
Why?
|
| Pain Management | 2 | 2016 | 668 | 0.440 |
Why?
|
| Longitudinal Studies | 5 | 2023 | 1945 | 0.440 |
Why?
|
| Young Adult | 21 | 2021 | 21445 | 0.440 |
Why?
|
| Delirium | 5 | 2001 | 207 | 0.440 |
Why?
|
| Gout Suppressants | 1 | 2012 | 21 | 0.440 |
Why?
|
| Musculoskeletal Pain | 1 | 2012 | 21 | 0.440 |
Why?
|
| Gout | 1 | 2012 | 31 | 0.440 |
Why?
|
| Incidence | 9 | 2022 | 5673 | 0.430 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 83 | 0.430 |
Why?
|
| Drug Overdose | 1 | 2013 | 81 | 0.430 |
Why?
|
| Societies, Medical | 7 | 2020 | 1335 | 0.430 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 335 | 0.420 |
Why?
|
| Melanoma | 4 | 2023 | 5317 | 0.420 |
Why?
|
| Body Mass Index | 2 | 2017 | 2203 | 0.410 |
Why?
|
| Polymyalgia Rheumatica | 2 | 2022 | 4 | 0.410 |
Why?
|
| Arthritis, Infectious | 1 | 2012 | 68 | 0.410 |
Why?
|
| Medical Oncology | 3 | 2020 | 1423 | 0.400 |
Why?
|
| Peer Review, Research | 3 | 2006 | 66 | 0.400 |
Why?
|
| Programmed Cell Death 1 Receptor | 8 | 2020 | 1048 | 0.390 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2013 | 184 | 0.390 |
Why?
|
| Epidemiologic Studies | 1 | 2011 | 60 | 0.390 |
Why?
|
| Cervical Vertebrae | 1 | 2012 | 205 | 0.390 |
Why?
|
| Clinical Trials as Topic | 10 | 2023 | 3719 | 0.380 |
Why?
|
| Candida | 1 | 2012 | 164 | 0.380 |
Why?
|
| Palliative Medicine | 5 | 2020 | 23 | 0.380 |
Why?
|
| Scleroderma, Limited | 1 | 2010 | 5 | 0.380 |
Why?
|
| Hypertension | 3 | 2017 | 1503 | 0.380 |
Why?
|
| Scleroderma, Diffuse | 1 | 2010 | 5 | 0.380 |
Why?
|
| Sickness Impact Profile | 2 | 2015 | 139 | 0.380 |
Why?
|
| Orthopedic Procedures | 1 | 2012 | 146 | 0.380 |
Why?
|
| International Agencies | 5 | 2020 | 107 | 0.380 |
Why?
|
| Cost-Benefit Analysis | 7 | 2021 | 945 | 0.370 |
Why?
|
| Interviews as Topic | 7 | 2018 | 497 | 0.370 |
Why?
|
| Airway Management | 1 | 2012 | 102 | 0.370 |
Why?
|
| Registries | 6 | 2021 | 2170 | 0.370 |
Why?
|
| Minority Groups | 3 | 2007 | 322 | 0.370 |
Why?
|
| Health Services | 3 | 2010 | 105 | 0.370 |
Why?
|
| Health Literacy | 3 | 2021 | 118 | 0.360 |
Why?
|
| Palliative Care | 8 | 2020 | 2037 | 0.360 |
Why?
|
| Hypercholesterolemia | 1 | 2012 | 259 | 0.360 |
Why?
|
| Candidiasis | 1 | 2012 | 262 | 0.360 |
Why?
|
| Self Report | 1 | 2013 | 756 | 0.350 |
Why?
|
| Patient Participation | 4 | 2019 | 446 | 0.340 |
Why?
|
| Pilot Projects | 4 | 2021 | 2803 | 0.340 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2012 | 605 | 0.340 |
Why?
|
| Cancer Care Facilities | 1 | 2013 | 884 | 0.330 |
Why?
|
| Health Education | 3 | 2021 | 309 | 0.330 |
Why?
|
| Patient Care | 1 | 2010 | 149 | 0.330 |
Why?
|
| History, 21st Century | 5 | 2020 | 441 | 0.330 |
Why?
|
| Health Planning Guidelines | 1 | 2008 | 58 | 0.320 |
Why?
|
| Antineoplastic Agents | 8 | 2019 | 14289 | 0.320 |
Why?
|
| Anesthesia | 1 | 2012 | 296 | 0.320 |
Why?
|
| Immunoglobulin G | 5 | 2009 | 1021 | 0.320 |
Why?
|
| Thiazoles | 1 | 2012 | 726 | 0.320 |
Why?
|
| Reproducibility of Results | 14 | 2018 | 6009 | 0.320 |
Why?
|
| Patient-Centered Care | 4 | 2021 | 294 | 0.320 |
Why?
|
| Hospitals, Pediatric | 1 | 2013 | 773 | 0.310 |
Why?
|
| Health Behavior | 2 | 2015 | 603 | 0.310 |
Why?
|
| Patient Preference | 1 | 2010 | 218 | 0.310 |
Why?
|
| Health Services Accessibility | 5 | 2007 | 761 | 0.310 |
Why?
|
| Infliximab | 6 | 2017 | 130 | 0.300 |
Why?
|
| Economics, Medical | 2 | 2003 | 15 | 0.300 |
Why?
|
| Diffusion of Innovation | 2 | 2006 | 160 | 0.300 |
Why?
|
| Family Practice | 2 | 1997 | 125 | 0.290 |
Why?
|
| Socioeconomic Factors | 7 | 2011 | 1225 | 0.290 |
Why?
|
| Disease Management | 3 | 2022 | 1052 | 0.290 |
Why?
|
| Etanercept | 6 | 2017 | 54 | 0.290 |
Why?
|
| Synovial Fluid | 2 | 2019 | 27 | 0.280 |
Why?
|
| Multivariate Analysis | 10 | 2013 | 4298 | 0.280 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2022 | 6550 | 0.280 |
Why?
|
| Terminally Ill | 2 | 2004 | 91 | 0.280 |
Why?
|
| Publishing | 1 | 2008 | 220 | 0.280 |
Why?
|
| Recovery of Function | 4 | 2015 | 703 | 0.280 |
Why?
|
| Intermittent Claudication | 2 | 2006 | 56 | 0.280 |
Why?
|
| Hepatitis B Core Antigens | 2 | 2018 | 27 | 0.280 |
Why?
|
| Walking | 2 | 2005 | 277 | 0.280 |
Why?
|
| Financing, Personal | 1 | 2005 | 19 | 0.270 |
Why?
|
| Appointments and Schedules | 2 | 2005 | 98 | 0.270 |
Why?
|
| Androgen Antagonists | 2 | 2022 | 411 | 0.270 |
Why?
|
| Trust | 1 | 2006 | 99 | 0.260 |
Why?
|
| Risk Assessment | 10 | 2021 | 6869 | 0.250 |
Why?
|
| Professional Practice | 1 | 2005 | 82 | 0.250 |
Why?
|
| Narcotics | 2 | 1995 | 123 | 0.250 |
Why?
|
| Hydroxychloroquine | 2 | 2003 | 32 | 0.250 |
Why?
|
| Radiography | 7 | 2017 | 1904 | 0.250 |
Why?
|
| Prevalence | 11 | 2020 | 3260 | 0.250 |
Why?
|
| Hepacivirus | 2 | 2020 | 397 | 0.250 |
Why?
|
| HIV Infections | 6 | 2015 | 2134 | 0.240 |
Why?
|
| Drug Therapy, Combination | 6 | 2018 | 2315 | 0.240 |
Why?
|
| Cost of Illness | 1 | 2007 | 498 | 0.240 |
Why?
|
| Receptors, Tumor Necrosis Factor | 5 | 2009 | 184 | 0.240 |
Why?
|
| Choice Behavior | 3 | 2019 | 226 | 0.230 |
Why?
|
| Inflammation | 2 | 2017 | 2522 | 0.230 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2021 | 2979 | 0.230 |
Why?
|
| Public Policy | 1 | 2003 | 60 | 0.230 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 177 | 0.230 |
Why?
|
| Alberta | 6 | 2009 | 65 | 0.230 |
Why?
|
| Efficiency | 1 | 2003 | 99 | 0.230 |
Why?
|
| Adolescent | 16 | 2021 | 31252 | 0.230 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2004 | 521 | 0.230 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2023 | 62 | 0.230 |
Why?
|
| Adalimumab | 5 | 2021 | 38 | 0.230 |
Why?
|
| Pyrroles | 2 | 2017 | 576 | 0.220 |
Why?
|
| Low Back Pain | 2 | 1997 | 83 | 0.220 |
Why?
|
| Postoperative Complications | 4 | 2012 | 5542 | 0.220 |
Why?
|
| Time Factors | 7 | 2021 | 12926 | 0.210 |
Why?
|
| Rheumatologists | 1 | 2022 | 10 | 0.210 |
Why?
|
| Glucocorticoids | 4 | 2000 | 629 | 0.210 |
Why?
|
| Antihypertensive Agents | 2 | 2017 | 395 | 0.210 |
Why?
|
| Giant Cell Arteritis | 1 | 2022 | 57 | 0.200 |
Why?
|
| Survival Rate | 7 | 2021 | 12221 | 0.200 |
Why?
|
| Electronics | 1 | 2021 | 58 | 0.200 |
Why?
|
| Piperidines | 2 | 2017 | 1035 | 0.200 |
Why?
|
| Symptom Flare Up | 1 | 2021 | 22 | 0.200 |
Why?
|
| Data Collection | 6 | 2009 | 620 | 0.200 |
Why?
|
| Community Health Services | 1 | 2002 | 126 | 0.200 |
Why?
|
| Survivorship | 1 | 2021 | 109 | 0.190 |
Why?
|
| Databases, Bibliographic | 1 | 2000 | 30 | 0.190 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2000 | 32 | 0.190 |
Why?
|
| MEDLINE | 1 | 2000 | 36 | 0.190 |
Why?
|
| Sjogren's Syndrome | 2 | 2019 | 102 | 0.190 |
Why?
|
| Lung Neoplasms | 5 | 2023 | 11538 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 7551 | 0.190 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2020 | 7 | 0.190 |
Why?
|
| Nicotine | 1 | 2022 | 244 | 0.190 |
Why?
|
| Elective Surgical Procedures | 1 | 2002 | 250 | 0.190 |
Why?
|
| Waiting Lists | 1 | 2002 | 263 | 0.190 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2020 | 26 | 0.190 |
Why?
|
| Logistic Models | 6 | 2017 | 3441 | 0.190 |
Why?
|
| Life Style | 3 | 2011 | 612 | 0.190 |
Why?
|
| Institutionalization | 1 | 2000 | 13 | 0.190 |
Why?
|
| Cyclophosphamide | 3 | 2022 | 3001 | 0.180 |
Why?
|
| Hepatitis C Antibodies | 1 | 2020 | 41 | 0.180 |
Why?
|
| Disabled Persons | 1 | 2001 | 121 | 0.180 |
Why?
|
| Endocrine System Diseases | 1 | 2020 | 83 | 0.180 |
Why?
|
| Endarterectomy, Carotid | 2 | 1999 | 121 | 0.180 |
Why?
|
| Risk | 4 | 2017 | 1972 | 0.180 |
Why?
|
| Information Storage and Retrieval | 1 | 2000 | 135 | 0.180 |
Why?
|
| Causality | 1 | 2020 | 178 | 0.180 |
Why?
|
| Deprescriptions | 1 | 2019 | 24 | 0.180 |
Why?
|
| HLA Antigens | 4 | 1994 | 546 | 0.180 |
Why?
|
| Symptom Assessment | 2 | 2019 | 267 | 0.170 |
Why?
|
| Homocysteine | 1 | 2020 | 138 | 0.170 |
Why?
|
| Arthritis, Psoriatic | 1 | 2019 | 17 | 0.170 |
Why?
|
| Cultural Diversity | 2 | 2013 | 76 | 0.170 |
Why?
|
| Carotid Stenosis | 2 | 1999 | 176 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 152 | 0.170 |
Why?
|
| Arthralgia | 1 | 2019 | 89 | 0.170 |
Why?
|
| Lupus Nephritis | 1 | 2019 | 48 | 0.170 |
Why?
|
| Physicians | 2 | 2012 | 882 | 0.170 |
Why?
|
| Androgens | 1 | 2022 | 511 | 0.170 |
Why?
|
| Health Information Systems | 1 | 2019 | 34 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2004 | 674 | 0.170 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2020 | 193 | 0.170 |
Why?
|
| Odds Ratio | 5 | 2012 | 2316 | 0.160 |
Why?
|
| Arthrography | 1 | 2018 | 9 | 0.160 |
Why?
|
| Isoxazoles | 3 | 2003 | 81 | 0.160 |
Why?
|
| Aromatase Inhibitors | 1 | 2021 | 305 | 0.160 |
Why?
|
| Drug Eruptions | 1 | 2020 | 256 | 0.160 |
Why?
|
| Primary Health Care | 4 | 2011 | 787 | 0.160 |
Why?
|
| Prognosis | 11 | 2021 | 21713 | 0.160 |
Why?
|
| Vocabulary | 1 | 2017 | 23 | 0.160 |
Why?
|
| Fluid Therapy | 3 | 2000 | 182 | 0.160 |
Why?
|
| Diagnosis, Differential | 6 | 2012 | 4744 | 0.160 |
Why?
|
| Physician's Role | 1 | 2020 | 238 | 0.160 |
Why?
|
| Graft vs Host Disease | 3 | 2021 | 2638 | 0.160 |
Why?
|
| Smoking | 3 | 2022 | 2440 | 0.160 |
Why?
|
| Psoriasis | 2 | 1990 | 126 | 0.160 |
Why?
|
| Immunization, Passive | 1 | 2018 | 172 | 0.160 |
Why?
|
| Geriatric Assessment | 2 | 2014 | 275 | 0.160 |
Why?
|
| Nephritis, Interstitial | 1 | 2019 | 76 | 0.160 |
Why?
|
| Endpoint Determination | 2 | 2007 | 176 | 0.150 |
Why?
|
| Recurrence | 2 | 2019 | 4758 | 0.150 |
Why?
|
| Perception | 1 | 2020 | 350 | 0.150 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 330 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 180 | 0.150 |
Why?
|
| International Cooperation | 4 | 2012 | 323 | 0.150 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 1997 | 37 | 0.150 |
Why?
|
| Health Services Research | 1 | 1999 | 233 | 0.150 |
Why?
|
| alpha-Linolenic Acid | 1 | 2017 | 17 | 0.150 |
Why?
|
| Medical Audit | 3 | 2013 | 188 | 0.150 |
Why?
|
| Immunomodulation | 1 | 2019 | 242 | 0.150 |
Why?
|
| Selection Bias | 1 | 2017 | 50 | 0.150 |
Why?
|
| Mexico | 4 | 2011 | 259 | 0.150 |
Why?
|
| Systole | 1 | 2017 | 196 | 0.150 |
Why?
|
| Terminal Care | 3 | 1999 | 447 | 0.140 |
Why?
|
| Motion Therapy, Continuous Passive | 2 | 2007 | 4 | 0.140 |
Why?
|
| Age Distribution | 3 | 2017 | 698 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2021 | 661 | 0.140 |
Why?
|
| Organ Transplantation | 1 | 2019 | 191 | 0.140 |
Why?
|
| Vaccination | 1 | 2023 | 1123 | 0.140 |
Why?
|
| Fish Oils | 1 | 2017 | 88 | 0.140 |
Why?
|
| Genotype | 2 | 2021 | 4109 | 0.140 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 14889 | 0.140 |
Why?
|
| Docosahexaenoic Acids | 1 | 2017 | 79 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2018 | 329 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 2 | 2020 | 589 | 0.140 |
Why?
|
| Activities of Daily Living | 4 | 2010 | 552 | 0.140 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2019 | 2326 | 0.140 |
Why?
|
| Haplotypes | 2 | 1990 | 856 | 0.140 |
Why?
|
| Metoclopramide | 1 | 1996 | 33 | 0.140 |
Why?
|
| Bias | 1 | 2017 | 205 | 0.140 |
Why?
|
| Demography | 2 | 2014 | 435 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2020 | 4938 | 0.140 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2017 | 92 | 0.140 |
Why?
|
| Hematologic Neoplasms | 2 | 2018 | 1870 | 0.140 |
Why?
|
| Hepatitis B, Chronic | 1 | 2017 | 137 | 0.130 |
Why?
|
| Abatacept | 4 | 2021 | 26 | 0.130 |
Why?
|
| Range of Motion, Articular | 2 | 2007 | 144 | 0.130 |
Why?
|
| Factor Analysis, Statistical | 3 | 2016 | 356 | 0.130 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2015 | 75 | 0.130 |
Why?
|
| Case-Control Studies | 4 | 2021 | 6100 | 0.130 |
Why?
|
| Gynecology | 1 | 1997 | 217 | 0.130 |
Why?
|
| Coronary Disease | 1 | 1999 | 764 | 0.130 |
Why?
|
| Publication Bias | 1 | 2015 | 38 | 0.130 |
Why?
|
| Antiemetics | 1 | 1996 | 125 | 0.130 |
Why?
|
| Mental Health | 2 | 2021 | 415 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2020 | 717 | 0.130 |
Why?
|
| Hepatitis C | 1 | 2020 | 524 | 0.130 |
Why?
|
| Graft Rejection | 1 | 2019 | 834 | 0.120 |
Why?
|
| Pyrimidines | 2 | 2017 | 3518 | 0.120 |
Why?
|
| Vomiting | 1 | 1996 | 354 | 0.120 |
Why?
|
| Coronary Artery Bypass | 1 | 1999 | 708 | 0.120 |
Why?
|
| Nausea | 1 | 1996 | 525 | 0.120 |
Why?
|
| Hepatitis A | 1 | 2013 | 32 | 0.120 |
Why?
|
| Fluoridation | 1 | 1993 | 3 | 0.120 |
Why?
|
| Confidence Intervals | 3 | 2017 | 756 | 0.110 |
Why?
|
| Salix | 1 | 2003 | 1 | 0.110 |
Why?
|
| Plant Bark | 1 | 2003 | 5 | 0.110 |
Why?
|
| Acupuncture Analgesia | 1 | 2012 | 2 | 0.110 |
Why?
|
| Moxibustion | 1 | 2012 | 9 | 0.110 |
Why?
|
| Sex Distribution | 4 | 2017 | 495 | 0.110 |
Why?
|
| Febuxostat | 1 | 2012 | 4 | 0.110 |
Why?
|
| Biomarkers | 3 | 2019 | 5047 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 1294 | 0.110 |
Why?
|
| Psychology | 1 | 2013 | 86 | 0.110 |
Why?
|
| Orchiectomy | 1 | 2013 | 214 | 0.110 |
Why?
|
| Quality Control | 2 | 2008 | 457 | 0.110 |
Why?
|
| Hemodynamics | 1 | 1997 | 935 | 0.110 |
Why?
|
| Korea | 1 | 2012 | 63 | 0.110 |
Why?
|
| Sulfuric Acids | 1 | 1992 | 7 | 0.110 |
Why?
|
| Grounded Theory | 1 | 2012 | 6 | 0.110 |
Why?
|
| Joints | 1 | 2012 | 47 | 0.110 |
Why?
|
| Alcoholism | 1 | 1995 | 285 | 0.110 |
Why?
|
| Vietnam | 1 | 2012 | 56 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 1998 | 899 | 0.110 |
Why?
|
| Hyperuricemia | 1 | 2012 | 34 | 0.110 |
Why?
|
| Air Pollutants, Occupational | 1 | 1992 | 30 | 0.110 |
Why?
|
| Allopurinol | 1 | 2012 | 54 | 0.110 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 1992 | 37 | 0.110 |
Why?
|
| Hepatitis B Antibodies | 1 | 2012 | 58 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2017 | 636 | 0.110 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2012 | 84 | 0.110 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 13658 | 0.110 |
Why?
|
| Medicare Part D | 1 | 2012 | 30 | 0.110 |
Why?
|
| Uncertainty | 1 | 2014 | 320 | 0.100 |
Why?
|
| Language | 3 | 2019 | 309 | 0.100 |
Why?
|
| Videotape Recording | 1 | 2012 | 74 | 0.100 |
Why?
|
| Drug Resistance, Fungal | 1 | 2012 | 92 | 0.100 |
Why?
|
| Synovitis | 1 | 2011 | 23 | 0.100 |
Why?
|
| Anti-HIV Agents | 2 | 2013 | 350 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 1303 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2330 | 0.100 |
Why?
|
| Kidney | 1 | 2000 | 2146 | 0.100 |
Why?
|
| Acculturation | 1 | 2012 | 112 | 0.100 |
Why?
|
| Klebsiella Infections | 1 | 1992 | 64 | 0.100 |
Why?
|
| Reoperation | 2 | 2007 | 1382 | 0.100 |
Why?
|
| Pneumonia | 1 | 2017 | 751 | 0.100 |
Why?
|
| Fiber Optic Technology | 1 | 2012 | 142 | 0.100 |
Why?
|
| Joint Instability | 1 | 2012 | 88 | 0.100 |
Why?
|
| Occupational Diseases | 1 | 1992 | 130 | 0.100 |
Why?
|
| Search Engine | 2 | 2022 | 21 | 0.100 |
Why?
|
| Lipoproteins | 1 | 2012 | 252 | 0.100 |
Why?
|
| Fractures, Spontaneous | 1 | 2011 | 84 | 0.100 |
Why?
|
| Medical Records | 1 | 2012 | 415 | 0.100 |
Why?
|
| Health Status Indicators | 2 | 2003 | 224 | 0.100 |
Why?
|
| China | 1 | 2012 | 606 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2017 | 787 | 0.100 |
Why?
|
| Acupuncture | 1 | 2010 | 22 | 0.100 |
Why?
|
| Placebo Effect | 1 | 2010 | 39 | 0.100 |
Why?
|
| Plant Extracts | 1 | 2003 | 215 | 0.100 |
Why?
|
| HLA-B27 Antigen | 4 | 1994 | 13 | 0.090 |
Why?
|
| Self-Examination | 1 | 2010 | 12 | 0.090 |
Why?
|
| Cyclosporine | 2 | 2003 | 278 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 2 | 2008 | 276 | 0.090 |
Why?
|
| Occupational Exposure | 1 | 1992 | 244 | 0.090 |
Why?
|
| Monitoring, Intraoperative | 1 | 2012 | 264 | 0.090 |
Why?
|
| Access to Information | 1 | 2010 | 65 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 280 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 313 | 0.090 |
Why?
|
| Canada | 4 | 2012 | 429 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2012 | 829 | 0.090 |
Why?
|
| Cytokines | 1 | 2019 | 2809 | 0.090 |
Why?
|
| Cultural Characteristics | 1 | 2010 | 70 | 0.090 |
Why?
|
| DNA, Viral | 1 | 2012 | 694 | 0.090 |
Why?
|
| Educational Status | 2 | 2008 | 397 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2017 | 1230 | 0.090 |
Why?
|
| Child | 7 | 2023 | 29154 | 0.090 |
Why?
|
| Sleep | 2 | 2009 | 413 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2016 | 1000 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2010 | 2307 | 0.080 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 483 | 0.080 |
Why?
|
| Anxiety | 1 | 2016 | 1179 | 0.080 |
Why?
|
| Patient Care Planning | 1 | 2011 | 297 | 0.080 |
Why?
|
| Transplantation, Homologous | 3 | 2021 | 2843 | 0.080 |
Why?
|
| Cognition | 1 | 1995 | 968 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 489 | 0.080 |
Why?
|
| Hepatitis C, Chronic | 1 | 2014 | 451 | 0.080 |
Why?
|
| Stakeholder Participation | 2 | 2019 | 38 | 0.080 |
Why?
|
| Journal Impact Factor | 1 | 2008 | 40 | 0.080 |
Why?
|
| Peer Review | 1 | 2008 | 80 | 0.080 |
Why?
|
| Bone and Bones | 1 | 2011 | 619 | 0.080 |
Why?
|
| Conflict of Interest | 1 | 2008 | 98 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 901 | 0.080 |
Why?
|
| Delphi Technique | 2 | 2019 | 210 | 0.080 |
Why?
|
| Self Concept | 1 | 2009 | 211 | 0.080 |
Why?
|
| Guidelines as Topic | 2 | 2006 | 383 | 0.080 |
Why?
|
| Length of Stay | 1 | 2014 | 1900 | 0.080 |
Why?
|
| Models, Theoretical | 3 | 2019 | 785 | 0.080 |
Why?
|
| Marriage | 1 | 2007 | 45 | 0.080 |
Why?
|
| Network Meta-Analysis | 2 | 2017 | 31 | 0.080 |
Why?
|
| Ethics, Medical | 1 | 2001 | 442 | 0.080 |
Why?
|
| Triglycerides | 1 | 2010 | 603 | 0.080 |
Why?
|
| Lower Extremity | 2 | 2007 | 299 | 0.080 |
Why?
|
| Medically Underserved Area | 1 | 2008 | 101 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2023 | 544 | 0.070 |
Why?
|
| Social Class | 2 | 2008 | 310 | 0.070 |
Why?
|
| Sulfasalazine | 2 | 2003 | 16 | 0.070 |
Why?
|
| Survival Analysis | 7 | 2017 | 9180 | 0.070 |
Why?
|
| Cholesterol | 1 | 2010 | 658 | 0.070 |
Why?
|
| Imidazoles | 1 | 2012 | 999 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 6207 | 0.070 |
Why?
|
| Sensitivity and Specificity | 5 | 2006 | 4971 | 0.070 |
Why?
|
| Community Participation | 1 | 2006 | 53 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 3869 | 0.070 |
Why?
|
| Principal Component Analysis | 1 | 2006 | 218 | 0.070 |
Why?
|
| Pulse | 1 | 2006 | 31 | 0.070 |
Why?
|
| Antifungal Agents | 1 | 2012 | 834 | 0.070 |
Why?
|
| Limb Salvage | 1 | 2007 | 162 | 0.070 |
Why?
|
| Palpation | 1 | 2006 | 49 | 0.070 |
Why?
|
| Depression | 1 | 2016 | 1715 | 0.070 |
Why?
|
| Joint Prosthesis | 1 | 2005 | 11 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2012 | 1529 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2008 | 291 | 0.070 |
Why?
|
| Hip Joint | 1 | 2005 | 54 | 0.070 |
Why?
|
| Predictive Value of Tests | 4 | 2004 | 4892 | 0.070 |
Why?
|
| Interpersonal Relations | 1 | 2007 | 290 | 0.060 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2006 | 160 | 0.060 |
Why?
|
| Regression Analysis | 3 | 2004 | 1546 | 0.060 |
Why?
|
| Leg | 1 | 2006 | 226 | 0.060 |
Why?
|
| Communication Barriers | 1 | 2005 | 52 | 0.060 |
Why?
|
| Truth Disclosure | 1 | 2006 | 180 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 3022 | 0.060 |
Why?
|
| Population Groups | 1 | 2004 | 42 | 0.060 |
Why?
|
| Drug and Narcotic Control | 1 | 2003 | 31 | 0.060 |
Why?
|
| Urban Population | 1 | 2005 | 269 | 0.060 |
Why?
|
| HLA-DR Antigens | 1 | 2004 | 173 | 0.060 |
Why?
|
| United States Agency for Healthcare Research and Quality | 2 | 1997 | 12 | 0.060 |
Why?
|
| Drug Costs | 1 | 2005 | 144 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2005 | 317 | 0.060 |
Why?
|
| Penicillamine | 1 | 2003 | 22 | 0.060 |
Why?
|
| Arthritis, Juvenile | 1 | 2004 | 51 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2021 | 3472 | 0.060 |
Why?
|
| Azathioprine | 1 | 2003 | 66 | 0.060 |
Why?
|
| Policy Making | 1 | 2003 | 85 | 0.060 |
Why?
|
| Auranofin | 1 | 2003 | 38 | 0.060 |
Why?
|
| Emotions | 1 | 2007 | 562 | 0.060 |
Why?
|
| Algorithms | 1 | 2014 | 3890 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 4557 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2003 | 185 | 0.050 |
Why?
|
| Bayes Theorem | 2 | 2017 | 1021 | 0.050 |
Why?
|
| B7-H1 Antigen | 2 | 2020 | 1022 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2005 | 1054 | 0.050 |
Why?
|
| Femoral Neck Fractures | 1 | 2001 | 11 | 0.050 |
Why?
|
| Europe | 2 | 2015 | 649 | 0.050 |
Why?
|
| Minocycline | 1 | 2003 | 182 | 0.050 |
Why?
|
| Poverty | 1 | 2005 | 471 | 0.050 |
Why?
|
| Health Care Rationing | 1 | 2002 | 94 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 4654 | 0.050 |
Why?
|
| Tissue Donors | 2 | 1996 | 769 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 4757 | 0.050 |
Why?
|
| Drug Information Services | 1 | 2000 | 11 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 6915 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2002 | 430 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2021 | 70 | 0.050 |
Why?
|
| Fatigue | 1 | 2007 | 1239 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1362 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2006 | 1171 | 0.050 |
Why?
|
| Linear Models | 1 | 2003 | 1085 | 0.050 |
Why?
|
| Public Health | 1 | 2002 | 299 | 0.040 |
Why?
|
| Spondylarthropathies | 1 | 2019 | 4 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2007 | 860 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2019 | 23 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2019 | 22 | 0.040 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 1996 | 35 | 0.040 |
Why?
|
| Semantics | 1 | 2019 | 58 | 0.040 |
Why?
|
| Lactation | 1 | 2000 | 210 | 0.040 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2009 | 103 | 0.040 |
Why?
|
| Analgesics, Opioid | 3 | 2000 | 1371 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2006 | 806 | 0.040 |
Why?
|
| Calcitonin | 1 | 2000 | 186 | 0.040 |
Why?
|
| Leucovorin | 1 | 2000 | 332 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2000 | 553 | 0.040 |
Why?
|
| Culture | 1 | 2019 | 100 | 0.040 |
Why?
|
| Life Expectancy | 1 | 1999 | 129 | 0.040 |
Why?
|
| Health Services Misuse | 1 | 1999 | 39 | 0.040 |
Why?
|
| Ossification of Posterior Longitudinal Ligament | 1 | 1998 | 3 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 1999 | 87 | 0.040 |
Why?
|
| Eye | 1 | 2000 | 301 | 0.040 |
Why?
|
| Decision Trees | 1 | 2019 | 178 | 0.040 |
Why?
|
| Age Factors | 5 | 1999 | 5377 | 0.040 |
Why?
|
| Global Health | 1 | 2003 | 657 | 0.040 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 109 | 0.040 |
Why?
|
| Immunocompromised Host | 2 | 2014 | 698 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 15862 | 0.040 |
Why?
|
| Health Resources | 1 | 2019 | 168 | 0.040 |
Why?
|
| Atherosclerosis | 1 | 2006 | 935 | 0.040 |
Why?
|
| Vitamin D | 1 | 2000 | 261 | 0.040 |
Why?
|
| Prejudice | 2 | 2008 | 57 | 0.040 |
Why?
|
| Infant | 1 | 2013 | 13310 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2020 | 671 | 0.040 |
Why?
|
| Bradycardia | 1 | 1997 | 70 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1997 | 105 | 0.040 |
Why?
|
| Polymyositis | 1 | 1996 | 9 | 0.040 |
Why?
|
| Endomyocardial Fibrosis | 1 | 1996 | 9 | 0.040 |
Why?
|
| Mitral Valve Prolapse | 1 | 1996 | 17 | 0.040 |
Why?
|
| Methylprednisolone | 1 | 2017 | 193 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 1997 | 142 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2013 | 16273 | 0.040 |
Why?
|
| Attitude | 1 | 1997 | 159 | 0.040 |
Why?
|
| Dermatomyositis | 1 | 1996 | 34 | 0.040 |
Why?
|
| Immunoconjugates | 2 | 2009 | 279 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 2292 | 0.030 |
Why?
|
| Lumbar Vertebrae | 1 | 1997 | 245 | 0.030 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 1995 | 46 | 0.030 |
Why?
|
| Hypotension | 1 | 1997 | 210 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2001 | 786 | 0.030 |
Why?
|
| Hydromorphone | 1 | 1995 | 58 | 0.030 |
Why?
|
| SEER Program | 1 | 2019 | 1000 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2015 | 96 | 0.030 |
Why?
|
| Veterans | 1 | 2006 | 1641 | 0.030 |
Why?
|
| Awareness | 1 | 2015 | 126 | 0.030 |
Why?
|
| Australia | 1 | 2015 | 225 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 1995 | 229 | 0.030 |
Why?
|
| Patient Selection | 1 | 2002 | 2055 | 0.030 |
Why?
|
| Reference Values | 1 | 2006 | 1099 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 1586 | 0.030 |
Why?
|
| North America | 1 | 2015 | 314 | 0.030 |
Why?
|
| Genes, MHC Class I | 1 | 1994 | 46 | 0.030 |
Why?
|
| HLA-A Antigens | 2 | 1994 | 102 | 0.030 |
Why?
|
| Obesity | 1 | 2007 | 2884 | 0.030 |
Why?
|
| Cause of Death | 1 | 1997 | 752 | 0.030 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 1994 | 67 | 0.030 |
Why?
|
| Methadone | 1 | 1995 | 195 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 1391 | 0.030 |
Why?
|
| Constipation | 1 | 1994 | 177 | 0.030 |
Why?
|
| Calcium | 1 | 2000 | 1537 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 1914 | 0.030 |
Why?
|
| Tears | 1 | 1994 | 181 | 0.030 |
Why?
|
| Ontario | 1 | 1992 | 98 | 0.030 |
Why?
|
| Louisiana | 1 | 1992 | 139 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 1996 | 435 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2012 | 61 | 0.030 |
Why?
|
| Klebsiella | 1 | 1992 | 8 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2017 | 558 | 0.030 |
Why?
|
| Intention | 1 | 2013 | 109 | 0.030 |
Why?
|
| Caregivers | 1 | 2018 | 677 | 0.030 |
Why?
|
| Patient Advocacy | 1 | 2012 | 92 | 0.030 |
Why?
|
| Gene Frequency | 2 | 1994 | 1163 | 0.020 |
Why?
|
| Cross Reactions | 1 | 1992 | 266 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 3443 | 0.020 |
Why?
|
| Program Development | 1 | 2012 | 261 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 1990 | 22 | 0.020 |
Why?
|
| Research Personnel | 1 | 2012 | 156 | 0.020 |
Why?
|
| Bone Diseases | 1 | 2011 | 143 | 0.020 |
Why?
|
| HLA-B Antigens | 1 | 1990 | 57 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 840 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 289 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2004 | 5539 | 0.020 |
Why?
|
| Remission Induction | 1 | 2006 | 3569 | 0.020 |
Why?
|
| Critical Illness | 1 | 1995 | 714 | 0.020 |
Why?
|
| Economics, Pharmaceutical | 1 | 2009 | 13 | 0.020 |
Why?
|
| Immunity | 1 | 1992 | 342 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 1350 | 0.020 |
Why?
|
| Latin America | 1 | 2009 | 115 | 0.020 |
Why?
|
| Clinical Competence | 1 | 1997 | 1270 | 0.020 |
Why?
|
| Occupations | 1 | 2008 | 50 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2009 | 94 | 0.020 |
Why?
|
| Laryngeal Neoplasms | 1 | 1992 | 518 | 0.020 |
Why?
|
| Antibodies | 1 | 1992 | 838 | 0.020 |
Why?
|
| Reference Standards | 1 | 2009 | 339 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 1993 | 338 | 0.020 |
Why?
|
| Health Surveys | 1 | 2009 | 402 | 0.020 |
Why?
|
| Exercise | 1 | 2015 | 1183 | 0.020 |
Why?
|
| Pedigree | 2 | 1994 | 1890 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 1990 | 538 | 0.020 |
Why?
|
| Spondylitis | 1 | 1987 | 7 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2014 | 1320 | 0.020 |
Why?
|
| Hospital Mortality | 2 | 2006 | 1274 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 586 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2007 | 297 | 0.020 |
Why?
|
| Health Policy | 1 | 2009 | 291 | 0.020 |
Why?
|
| Brachial Artery | 1 | 2005 | 38 | 0.020 |
Why?
|
| Sex Factors | 2 | 1998 | 2139 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2007 | 305 | 0.020 |
Why?
|
| Diabetic Angiopathies | 1 | 2005 | 78 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2005 | 276 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 2007 | 397 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2006 | 298 | 0.020 |
Why?
|
| Economics | 1 | 2003 | 11 | 0.010 |
Why?
|
| HLA-DRB1 Chains | 1 | 2004 | 82 | 0.010 |
Why?
|
| Models, Biological | 1 | 1992 | 3254 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2007 | 1244 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2004 | 447 | 0.010 |
Why?
|
| ROC Curve | 1 | 2005 | 1183 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 10035 | 0.010 |
Why?
|
| Epitopes | 1 | 2004 | 685 | 0.010 |
Why?
|
| Precipitating Factors | 1 | 2000 | 6 | 0.010 |
Why?
|
| Dehydration | 1 | 2000 | 87 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 10331 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2000 | 209 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 3578 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2000 | 242 | 0.010 |
Why?
|
| Spinal Diseases | 1 | 1998 | 125 | 0.010 |
Why?
|
| Hypoxia | 1 | 2000 | 443 | 0.010 |
Why?
|
| Angiocardiography | 1 | 1996 | 15 | 0.010 |
Why?
|
| Spine | 1 | 1998 | 293 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2000 | 551 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 1999 | 251 | 0.010 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 1996 | 66 | 0.010 |
Why?
|
| Spirometry | 1 | 1996 | 143 | 0.010 |
Why?
|
| Suppositories | 1 | 1995 | 12 | 0.010 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 1996 | 126 | 0.010 |
Why?
|
| Capsules | 1 | 1995 | 53 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1995 | 191 | 0.010 |
Why?
|
| Phenotype | 1 | 1987 | 6295 | 0.010 |
Why?
|
| Cadaver | 1 | 1995 | 237 | 0.010 |
Why?
|
| Hospital Units | 1 | 1994 | 38 | 0.010 |
Why?
|
| Secretory Rate | 1 | 1994 | 16 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1996 | 475 | 0.010 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 1994 | 49 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1994 | 239 | 0.010 |
Why?
|
| Cell Separation | 1 | 1995 | 612 | 0.010 |
Why?
|
| Diabetic Neuropathies | 1 | 1994 | 101 | 0.010 |
Why?
|
| Tissue and Organ Procurement | 1 | 1996 | 233 | 0.010 |
Why?
|
| Family Health | 1 | 1994 | 325 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1994 | 512 | 0.010 |
Why?
|
| Colon | 1 | 1994 | 670 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1994 | 1471 | 0.010 |
Why?
|
| Research | 1 | 1993 | 415 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1995 | 2588 | 0.010 |
Why?
|
| Alleles | 1 | 1994 | 2437 | 0.000 |
Why?
|
| DNA | 1 | 1994 | 2693 | 0.000 |
Why?
|
| Antibodies, Antinuclear | 1 | 1985 | 46 | 0.000 |
Why?
|
| Serologic Tests | 1 | 1985 | 137 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1985 | 1062 | 0.000 |
Why?
|
| Cardiac Catheterization | 1 | 1985 | 687 | 0.000 |
Why?
|
| Echocardiography | 1 | 1985 | 1182 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1985 | 1145 | 0.000 |
Why?
|
| Animals | 1 | 1993 | 59536 | 0.000 |
Why?
|